- Home
- VSTM vs SLP Comparison
VSTM vs SLP Comparison
Compare VSTM & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | SLP |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.4M | 367.9M |
| IPO Year | 2011 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VSTM | SLP |
|---|---|---|
| Price | $5.89 | $18.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $16.50 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.2M | 692.5K |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $30,914,000.00 | ★ $59,577,000.00 |
| Revenue This Year | $282.64 | $3.80 |
| Revenue Next Year | $72.25 | $5.90 |
| P/E Ratio | ★ N/A | $42.40 |
| Revenue Growth | ★ 209.14 | 10.52 |
| 52 Week Low | $3.43 | $11.09 |
| 52 Week High | $11.25 | $21.01 |
Technical Indicators
Market Signals| Indicator | VSTM | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 67.17 | 62.90 |
| Support Level | $5.53 | $17.74 |
| Resistance Level | $6.48 | $18.57 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 85.31 | 20.69 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.